J&J Sales Beat Expectations on Strong Cancer Medicine Growth

Johnson & Johnson reported first-quarter sales above Wall Street’s expectations and bumped up its outlook for the year, led by strong growth of new cancer medicines and a drug for treatment-resistant depression.

Adjusted earnings of $2.70 a share came in one cent above the average of analyst estimates in a Bloomberg survey. Sales in the quarter beat expectations, and J&J increased its guidance for 2026 sales and profit.